Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Februar 2026 01:00 ET | Quelle: Clariant International Ltd

Clariant delivers third year of strong EBITDA margin improvement – EBITDA margin before exceptional items up 180 basis points versus prior year to 17.8 %

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR FOURTH QUARTER / FULL YEAR | 2025 Q4 2025 sales increased by 1 % in local currencies1 to CHF 1.028 billion due to strong volume growth in Catalysts and...
25. Februar 2026 08:00 ET | Quelle: Novo Nordisk A/S

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Novo Nordisk and Vivtex Corp announced partnership to develop next-generation oral biologic medicines for obesity, diabetes + associated comorbidities
24. Februar 2026 03:39 ET | Quelle: Novo Nordisk A/S

Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

The United Laboratories International Holdings Limited and Novo Nordisk today announced topline results from a Chinese phase 2 trial of UBT251
23. Februar 2026 07:24 ET | Quelle: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 23 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
23. Februar 2026 04:33 ET | Quelle: Novo Nordisk A/S

Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved

CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84...
20. Februar 2026 07:02 ET | Quelle: Novo Nordisk A/S

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 20 February 2026 – The Annual General Meeting will be held on: Thursday 26 March 2026 at 14:00 (CET) The Annual General Meeting will be held as a combined physical and virtual...
17. Februar 2026 08:58 ET | Quelle: Novo Nordisk A/S

Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average

Final EU approval of high-maintenance dose of Wegovy. The new dose gives healthcare professionals even more flexibility to tailor treatment.
16. Februar 2026 07:21 ET | Quelle: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
12. Februar 2026 04:15 ET | Quelle: Finnvera

Finnvera-konsernin toimintakertomus ja tilinpäätös 2025

Finnvera-konserni, pörssitiedote 12.2.2026 Finnvera-konsernin toimintakertomus ja tilinpäätös 2025 Viennin rahoituksen myöntäminen erittäin korkealla, myös kotimaan rahoitus kasvoi vertailukaudesta...
12. Februar 2026 04:15 ET | Quelle: Finnvera

Finnvera Group Report of the Board of Directors and Financial Statements 2025

Finnvera Group, Stock Exchange Release 12 February 2026 Report of the Board of Directors and Financial Statements 2025 The volume of granted export financing was extremely high, domestic financing...

Vorherige Seite

Nächste Seite